中低收入国家1型和2型糖尿病患者的肾脏病筛查、患病率、治疗与控制:IDMPS研究(2005-2017)
该研究基于IDMPS多波次非干预性数据,分析2005-2017年中低收入国家15,079例1型及66,088例2型糖尿病患者的肾脏病管理。结果显示肾脏病筛查率在W2至W3上升后趋于平稳,微量白蛋白尿和蛋白尿比例下降,透析报告率降低,他汀类和ARB使用增加。
要点
- 中低收入国家糖尿病肾脏病筛查率提升后平台,1型达83.4%,2型达86.2%(W7)。
- 微量白蛋白尿和蛋白尿比例随波次下降,透析报告率降低。
- 合并高血压者中ARB使用增加,ACEI使用减少;合并血脂异常者他汀使用增加。
核心结论
- 中低收入国家非肾脏科门诊的1型和2型糖尿病患者肾脏病筛查与治疗有所改善,微量白蛋白尿、蛋白尿比例及透析报告率下降。
研究设计与样本
- 国际糖尿病管理实践研究(IDMPS)为持续非干预性研究,纳入中低收入国家主要由内科医生和内分泌科医生提供门诊治疗的患者,分析2005-2017年七个波次数据,包括15,079例1型糖尿病和66,088例2型糖尿病患者。
主要发现
- 肾脏病筛查率在W2至W3上升后平台:1型糖尿病W2为73.7%、W3为84.1%、W7为83.4%;2型糖尿病W2为65.1%、W3为82.6%、W7为86.2%。
- 微量白蛋白尿比例下降:1型糖尿病W1为27.1%、W3为14.7%、W7为13.8%;2型糖尿病W1为24.5%、W3为12.6%、W7为11.9%。
- 蛋白尿比例下降:1型糖尿病W1为14.2%、W3为8.7%、W7为8.2%;2型糖尿病W1为15.6%、W3为9.3%、W7为7.6%。
- 报告接受透析的患者比例下降:1型糖尿病W2为1.4%、W7为0.3%;2型糖尿病W2为0.9%、W7为0.2%。
- 确诊血脂异常者他汀使用增加:1型糖尿病W1为77.7%、W7为90.7%;2型糖尿病W1为78.6%、W7为94.7%;确诊高血压者ARB使用增加:1型糖尿病W1为18.0%、W7为30.6%;2型糖尿病W1为24.2%、W7为43.6%,而ACEI使用下降:1型糖尿病W1为65.0%、W7为55.9%;2型糖尿病W1为55.7%、W7为41.1%。
临床怎么用
- 在中低收入国家非肾脏科门诊,应持续对1型和2型糖尿病患者进行肾脏病筛查,并优化降压(ARB/ACEI)和降脂治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes is the leading cause of kidney disease worldwide. There is limited information on screening, treatment and control of kidney disease in patients with diabetes in low-to-middle-income countries (LMICs). METHODS: The International Diabetes Management Practices Study is an ongoing, non-interventional study of clinical profiles and practices among patients receiving outpatient care mainly by internal medicine physicians and endocrinologists in LMICs. We examined screening, prevalence, treatment and control of kidney disease across seven waves (W) of data collection between 2005 and 2017. RESULTS: Among 15,079 patients with type 1 and 66,088 patients with type 2 diabetes, screening for kidney disease increased between W2 and W3 followed by a plateau (type 1 diabetes: W2, 73.7%; W3, 84.1%; W7, 83.4%; type 2 diabetes: W2, 65.1%; W3, 82.6%; W7, 86.2%). There were also decreasing proportions of patients with microalbuminuria (type 1 diabetes: W1, 27.1%; W3, 14.7%; W7, 13.8%; type 2 diabetes: W1, 24.5%; W3, 12.6%; W7, 11.9%) and proteinuria (type 1 diabetes: W1, 14.2%; W3, 8.7%; W7, 8.2%; type 2 diabetes: W1, 15.6%; W3, 9.3%; W7, 7.6%). Fewer patients were reported as receiving dialysis for both type 1 diabetes (W2, 1.4%; W7, 0.3%) and type 2 diabetes (W2, 0.9%; W7, 0.2%) over time. While there was no change in mean HbA1c or prevalence of diagnosed hypertension (type 1 diabetes: W1, 22.7%; W7, 19.9%; type 2 diabetes: W1, 60.9%; W7, 66.2%), the use of statins had increased among patients diagnosed with dyslipidaemia (type 1 diabetes: W1, 77.7%; W7, 90.7%; type 2 diabetes: W1, 78.6%; W7, 94.7%). Angiotensin II receptor blockers (type 1 diabetes: W1, 18.0%; W7, 30.6%; type 2 diabetes: W1, 24.2%; W7, 43.6%) were increasingly used over ACE inhibitors after W1 (type 1 diabetes: W1, 65.0%; W7, 55.9%; type 2 diabetes: W1, 55.7%, W7, 41.1%) among patients diagnosed with hypertension. CONCLUSIONS/INTERPRETATION: In LMICs, real-world data suggest improvement in screening and treatment for kidney disease in patients with type 1 and type 2 diabetes attending non-nephrology clinics. This was accompanied by decreasing proportions of patients with microalbuminuria and proteinuria, with fewer patients who reported receiving dialysis over a 12-year period.
引用
- Mbanya JC, Aschner P, Gagliardino JJ, et al. Screening, prevalence, treatment and control of kidney disease in patients with type 1 and type 2 diabetes in low-to-middle-income countries (2005-2017): the International Diabetes Management Practices Study (IDMPS). Diabetologia. 2021. PMID: 33594476. doi:10.1007/s00125-021-05406-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。